Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vildagliptin AM · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| vildagliptin am | EXPERIMENTAL | - |
| vildagliptin pm | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Vildagliptin AM | DRUG | - |
| vildagliptin pm | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * Patients on metformin for at least three months and on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1 * Body mass index in the range 22-40 * Blood glucose criteria must be met Exclusion Criteria: * Pregnancy or lactation * History of type 1...
Vildagliptin AM is being developed for the treatment of type 2 diabetes mellitus. It is a small molecule DPP4 inhibitor studied as an add-on therapy to metformin in adult patients whose blood glucose is not adequately controlled. The program is in Phase 3 development and is sponsored by Novartis AG.
Vildagliptin AM targets DPP4, also known as dipeptidyl peptidase-4. It acts as a DPP4 inhibitor, a class of oral small molecule agents used in type 2 diabetes. By inhibiting this enzyme, the drug belongs to the DPP4 inhibitor therapeutic class. The molecular target is listed in ChEMBL under identifier CHEMBL142703.
Vildagliptin AM is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program for this DPP4 inhibitor in type 2 diabetes mellitus. The asset sits within the metabolic therapeutic area.
Vildagliptin AM is in Phase 3 development for type 2 diabetes mellitus. It is an investigational small molecule DPP4 inhibitor and is not described as approved. The Phase 3 program includes one completed trial, and no active trials are currently listed for this asset.
Vildagliptin AM has been studied in the Phase 3 trial NCT00351884, titled Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes. That trial enrolled 370 adults, was randomized, double-blind, and placebo-controlled, and was conducted in the United States and Germany. It is now completed.